The KBM5 cells expressing reduced levels of SALL4 grew slowly. To better explain this phenomenon, we measured the level of caspase-3, which is a marker for the apoptosis-signaling pathway. In KBM5 cells that retained 50% of the WT levels of SALL4, there was a threefold increase of caspase-3 activity from 27.9% in WT cells to 93.6% in cells with reduced SALL4 levels as measured by FACS (Figure 2b) .
An exclusive production of light chains can be found in B15% of myeloma cases, and in these light-chain multiple myeloma (LC-MM) cases, the phenotype remains unchanged throughout subsequent progression and relapse. Once established, it suggests that this phenotype is maintained by the 'feeder cell' that re-populates the tumor bulk as disease re-emerges. This raises an important question of what the nature of the 'feeder cell' is that perpetuates disease, a question of wider relevance in multiple myeloma (MM), and how the 'feeder cell' is derived from the cell of origin that gives rise to disease.
In defining the cell of origin in MM and other B-cell tumors, immunoglobulin (Ig) variable (IGV) region gene analyses have provided important insights, relying on well-defined events in normal B-cell maturation to establish clonal history. In normal B-cells, IGV assembly occurs early with signature CDR3 motifs 1 to constitute functional sIg molecules, allowing exit from the bone marrow (BM). These peripheral B-cells, on recognizing antigen via sIg in secondary lymphoid follicles initiate the germinal center reaction and undergo somatic hypermutation (SHM) of IGV genes. Deletional isotype class switch recombination (CSR) at the chromosome 14q32 locus can also occur in germinal centers to alter effector function. 2 IGV analysis can track such events as they relate to malignant B-cell origins.
In typical isotype switched MM, extensive SHM but with no intraclonal variation in the pattern of mutations is consistent with neoplastic transformation occurring at a post-germinal center or post-follicular stage when SHM has ceased. 3 This pattern of SHM is also evident in LC-MM IGHV genes from an earlier study. 4 Clearly, the cell of origin in MM is sIg þ ve to initiate SHM, but whether such a cell persists and 'feeds' tumor growth has remained a matter of conjecture. CSR events in MM most likely also underlie frequent 14q32 chromosomal translocations evident at disease presentation and during disease course, and these genomic lesions together with others define profound tumor heterogeneity in MM. 5 This raises a further question of how this heterogeneity is maintained and whether there are differences between 'feeder cells' in different disease subsets. An additional question that needs to be addressed is the intraclonal variation observed within a given tumor clone in MM, in which different cells can exhibit distinct molecular lesions, as for example, shown by immunofluorescence in-situ hybridization.
6 Does this variation also arise from different 'feeder cells' within a single clone?
More recently, the previous uncertainty regarding a sIg þ ve precursor cell has been revisited. In these studies, a myeloma stem cell (MSC) has been reported as a CD138 Àve memory B-cell that is, surprisingly, sIg þ ve (in two cell lines, RPMI 8226 and NCI-H929). These MSCs were shown to confer clonogenicity in-vitro, and when isolated were able to engraft tumor in immunodeficient mice, whereas CD138 þ ve MM tumor cells failed to engraft. 7 The MSCs have been consistently described as CD19 þ CD27 þ memory B-cells by the Matsui laboratory, invoking a sIg þ status, [7] [8] [9] [10] and not as plasmablasts. An intrinsic feature of this proposed MSC model is that a less differentiated cell is able to feed the CD138 þ plasma cell (PC) tumor bulk.
The MSC seems to fit key elements of the stem cell (SC) paradigm in cancer, which has recently emerged as a model to understand malignant growth. In the cancer SC model, only a distinct usually minor pool of cells within a clonal hierarchy feed tumor growth. 11 As such, these cancer stem cells would be expected to have the potential to be able to self-renew and also differentiate to feed the tumor bulk. Such cancer stem cells have been investigated for SC gene signatures and allied signaling pathways, and also for their ability to resist chemotherapy. In MM, the Matsui laboratory has reported that the MSC is chemoresistant, and identified hedgehog signaling as a key feature. 10, 12 Furthermore, in MM the implication from the MSC studies is that a potential sIg þ MSC persists in all forms of the disease. Such a cell would be required to recapitulate the striking molecular heterogeneity seen in this disease.
In this study, we report on our analysis of LC-MM as a model to assess the MSC paradigm in MM. We used IGV analysis to examine whether a less differentiated cell exists in different B-cell compartments, as a putative 'MSC' that exhibits evidence for intact IGH and IGL genes that would be required to constitute sIg expression, trackable as clone-specific functional IGHV and IGLV genes. Peripheral blood (PB) and BM was obtained from six patients with active LC-MM at diagnosis following informed consent. Fluorescence in-situ hybridization analysis was routinely carried out for all patients. Sorting of B-cell subsets and PCs from BM and PB mononuclear cells (BMMNCs and PBMNCs, respectively) was carried out in a FACSAria flow cytometer (BD Biosciences, San Jose, CA, USA) as previously described. 13 Tumor-derived IGHV and IGLV were identified from genomic DNA or complementary DNA using our established protocols (Supplementary Figure; Supplementary Table). 14 IGHV CDR3-specific primers were used for single-stage and semi-nested PCR or reverse transcription-PCR analyses of subfractions or single cells as reported previously. 15 Clonal tumor-derived IGLV transcripts for the light chain were readily identified in 6/6 cases using complementary DNA derived from purified CD138 þ ve tumor cells (Table 1) . These revealed somatic mutations without intraclonal variation, consistent with reported origins of MM from a post-follicular B cell. 3 In contrast, no clonal IGHV transcripts were identifiable using multiplexed generic IGHV family primers (Table 1) , indicating the absence of mRNA, one cause of which is deleted V(D)J rearrangement on the functional allele, as proposed in a previous study. 4 To examine this, we analyzed IGHV genes using genomic DNA. In these assays, 3/6 cases (#1, 2, 4) revealed a potentially functional V(D)J rearrangement (V3-15, V4-39 and V3-33; Table 1 ). In 3/6 cases (#3, 5, 6), genomic IGHV genes seemed to have been deleted (Table 1 ). In one case (#4), two 14q32 lesions were observed, suggesting a second late event that locates upstream of the functional IGHV recombination. Dual and secondary translocations have also been mapped in typical MM. 5 Using CDR3-specific oligonucleotides, nested-PCR assays were carried out to examine complementary DNA from BM and PB MNCs in these cases (#1, 2, 4). No tumor-derived IGHV transcripts could be identified in two cases (#1, 4). In the remaining case (#2), these assays identified clonal IGHV transcripts in both whole BM and PB populations (10/10 clones were identical; data not shown). Detection excluded amplification of genomic DNA, as intronic sequences downstream of leader were absent. Clonal IGHV transcripts remained detectable in consecutive BM samples from case #2, but not in PB.
For further analyses in case #2, BM and PB MNCs were sorted into different B-cell subsets (naïve, IgM þ , IgM Àve B-cells, plasmablasts, PCs; purity 96 ± 3%), and examined for the existence of clonally related cells. Clone-specific IGHV sequences could only be detected in the PC fraction (confirmed by sequence analysis) and were absent in all other B-cell subfractions (Figure 1 ). Reported studies on nested PCR strategies to identify rearranged IGHV genes in B-cell tumors have defined the sensitivity of this technique at 10 À5 to 10 À6 using complementary DNA templates. 16 Importantly, cells Letters to the Editor expressing clonal IGLV transcripts were also not detectable using a clone-specific leader-CDR3 assay in any B-cell subset, indicating that any aberrant B-cells indicative of unusual 'precursors' expressing only light chain were absent.
The frequency of IGHV expressing cells within the clonal PC population in case #2 was sought by single cell analysis, and in 4/50 (8%) a clonal IGHV sequence was identifiable. These data reveal an on-going evolution of tumor at the PC level, suggesting 
. BM malignant PCs were sorted according to their phenotypic profile (CD19
. Malignant PCs were also detected at a very low frequency in the PB showing the same phenotype as their BM counterpart and again sorted according to this marker profile. Purity of the sorted subsets was 96±3%. Nested PCR was carried out as described in the methods section. IGLV_cDNA, IGLV primers, amplification from cDNA; IGHV_cDNA, IGHV primers, amplification from cDNA; b-ACT, beta-actin control for cDNA quality; IGHV_gen, IGHV primers, amplification from genomic DNA; Control, unrelated intronic control for DNA quality. 18 This suggests that xenotransplantation in earlier MSC studies may lack an appropriate niche provision to adequately assess the MM clonal hierarchy, 7 as the CD19 þ CD38 low CD138 Àve fraction should contain a sIg þ fraction. Coupled with our findings, we postulate an on-going intraclonal evolution of malignant PCs (possibly including CD138 þ clonal plasmablasts) to feed MM growth. The underlying genetic lesions that drive evolution of malignant PCs remain undefined, but include a 14q32 lesion in many MM, including LC-MM. Recently K-RAS mutations were associated only with myeloma PCs, but not aberrant memory B cells, 19 in support of a model of clonal evolution at the PC level in MM.
The role of a MSC as a 'feeder cell' in maintaining the genotype in MM in disease presentation and relapse has to address key conceptual requirements. This may be illustrated by the LC-MM model via two features. First, in postulating a sIg þ MSC in LC-MM, the assumption would be that such a cell continuously triggers the molecular lesions that lead to genomic deletion or silencing of the IGHV locus necessary for IgH assembly in order to populate the tumor bulk with the light-chain phenotype (Figure 2) . Second, that during these events a sIg þ MSC pool is maintained for subsequent feeder cycles (Figure 2 ). The occurrence of these multiple synchronized on-going events in sIg þ MSCs to feed LC-MM seems highly unlikely. This suggests that the 'feeder cell' in LC-MM arises late, having lost or silenced the rearranged IGHV locus. In MM generally then, it also seems unlikely that a rapid acquisition of all genetic abnormalities could occur in progeny derived from a sIg þ MSC as it cycles to feed the CD138 þ tumor bulk, including on relapse ( Figure 2 ). Disease progression in MM is known to retain marker chromosomal and genetic lesions, or acquires additional aberrant changes. Such a genotype, including epigenetic, would need to be reinstated by any less differentiated 'feeder cell' or MSC during disease course. It seems only to be feasible, if tumor growth is fed by malignant PCs with the full repertoire of genetic lesions.
